Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report
© Gupta et al; licensee BioMed Central Ltd. 2011
Received: 10 June 2011
Accepted: 5 October 2011
Published: 5 October 2011
Malignant tumors of the nasal cavity are rare. We report the case of a 48 years old man who consulted us with a 2-year history of progressive nasal obstruction, occasional epistaxis, facial pain, and watering of the eyes. A diagnosis of olfactory neuroblastoma was established by histopathology and confirmed by immunohistochemistry. On staging, the mass was classified as a Kadish stage C tumor with extensive involvement of the nasal cavities, nasopharynx, paranasal sinuses and orbit. Endoscopic excision of the mass was done. Traditionally the mainstay of treatment in such locally advanced patients is craniofacial resection followed by adjuvant radiotherapy. Our patient was treated with limited surgery and chemoradiation. Patient is free of recurrence at a follow-up of 5 years. This case report demonstrates the potential efficacy of planned combined modality therapy, including limited surgery and early chemoradiation in the control of locally advanced olfactory neuroblastoma.
Malignant tumors of the nasal cavity are rare. Olfactory neuroblastomas also known as esthesioneuroblastomas (ENB) is a rare and aggressive malignant tumor accounting for only 6% of nasal cavity and paranasal sinus neoplasms and 0.3% of the upper aero digestive tract malignancies . Treatment recommendations range from a minimally invasive approach to combined modality treatment including craniofacial resection and chemo radiotherapy .
In June 2004, a 48 year old male presented with progressive bilateral nasal obstruction, and bleeding through nostrils since 3 years associated with facial pain and blurred left eye vision from 6 months.
Immunohistochemistry profile (figure 2c and 2d) showed positivity for neural marker namely neuron specific enolase. The tumor cells were negative for epithelial markers cytokeratin and epithelial membrane antigen (figure 2e and 2f) Hence a diagnosis of adult esthesioneuroblastoma of nasal cavity was made.
Patient was planned for upfront chemotherapy followed by radiotherapy in June 2004. Surgical excision in form of craniofacial surgical resection was not done due to non-availability of technical advances and surgical expertise. Patient received 6 cycles of cisplatin (20 mg/m2 day1-5), etoposide (100 mg/m2 day1-5) and bleomycin (30 mg day2, 9 and 16) at 3 weekly interval, followed by external beam radiotherapy. Radiotherapy was planned with one anterior and two lateral wedge pair fields with unequal weighting and treatment was delivered via Telecobalt Unit Theratron 780C ( AECL, Ottawa, Canada) with dose normalized at tumor center. Dose homogeneity requirement was 95-105% of the specified centrally absorbed dose, as mentioned in the ICRU 50-reference point. Two-dimensional computer planning was done on Radplan software (TSG Corporation, India). Patient received total dose of 56Gy in 28 fractions in 5 1/2 weeks.
Our patient who presented with locally advanced disease Kadish stage C without intracranial extension was treated with limited surgery combined with chemoradiotherapy which has shown good response and disease free survival of 5 years. Presently our patient is clinically and radiologically free of disease.
Craniofacial surgery is the mainstay of treatment in ENB regardless of stage and grade with the possible exception of distance metastasis followed by adjuvant radiation in high grade and locally advanced tumors. . In unresectable ENB the experience with chemoradiation is lacking and is under-reported probably due to limited cases, but some of the latest series have shown promising results in nonsurgical approach .
Encouraged by these results we treated our patient who had locally advanced disease by limited surgery due to non-availability of technical advances and surgical expertise followed by chemo radiation, with excellent clinical outcome.
Chemoradiation along with limited surgery can be considered as one of the treatment modalility for locally advanced ENB with promising results.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Svane-Knudsen V, Jorgensen KE, Hansen O, Lindgren A, Marker P: Cancer of the nasal cavityand paranasal sinuses: a series of 115 patients. Rhinology. 1998, 36: 12-4.PubMedGoogle Scholar
- Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC: Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch otolaryngol head neck surg. 1997, 123: 34-40.View ArticlePubMedGoogle Scholar
- Foote RL, Morita A, Ebersold MJ, Olsen KD, Lewis JE, Quast LM, Ferguson JA, O'Fallon WM: Esthesioneuroblastoma. The role of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 1993, 27: 835-42. 10.1016/0360-3016(93)90457-7.View ArticlePubMedGoogle Scholar
- Broich G, Pagliari A, Ottaviani F: Esthesioneuroblastoma. A general review of the cases published since the discovery of the tumor in 1924. Anticancer Res. 1997, 17: 2683-706.PubMedGoogle Scholar
- Biller HF, Lawson W, Sachdev VP, Som P: Esthesioneuroblastoma: Surgical treatment without radiation. Laryngoscope. 1990, 100: 1199-1201.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.